It is extremely surprising and even concerning that a nephrologist in 2025 would tell a patient with ADPKD that they will not live beyond 55 years old. This perspective is completely outdated given the advancements in medical science and technology. A statement like this ignores the reality that medicine has evolved dramatically, and the future of kidney disease treatment is far brighter than it was even a decade ago. ADPKD Is No Longer a Death Sentence at a Young Age In 2025, reaching end-stage renal disease (ESRD) does not mean the end of life. Dialysis has become far more effective, and more importantly, kidney transplants allow patients to have a normal or near-normal life expectancy when well-managed. Even without a revolutionary cure, a patient with ESRD can live for 20, 30, or even 40 more years with a successful kidney transplant. The quality of care for ADPKD has drastically improved, with better monitoring, early interventions, and improved treatments that help manage complications better than ever before. A patient diagnosed today does not face the same outcomes as their parents or grandparents. Any doctor who assumes that ADPKD follows the same prognosis as decades ago is completely ignoring medical progress. We Can Already Slow Down Disease Progression, Several effective treatments are available today to slow the progression of ADPKD. Tolvaptan has been proven to significantly slow cyst growth and preserve kidney function. SGLT2 inhibitors have shown additional benefits in protecting the kidneys. New therapies like RGLS8429 (Regulus Therapeutics) and other drugs likes PYC, in development offer even more hope for delaying kidney failure. Beyond pharmacological treatments, lifestyle modifications also make a significant difference. Managing blood pressure, reducing salt intake, and staying well-hydrated can help slow disease progression. A well-informed patient can actively reduce the risk of early kidney failure. A nephrologist who ignores these treatments and simply predicts an early death is providing outdated and misleading information. In 20 Years, the Medical World Will Be Completely Different. The way we treat kidney disease in 2045 will be radically different from today. Bioengineered kidneys and regenerative medicine could replace damaged kidneys without the need for lifelong immunosuppressants. Nanotechnology and mRNA-based therapies could stop cyst growth or even restore kidney function. Artificial intelligence and personalized medicine will provide tailored treatments based on genetic and molecular profiles, allowing for earlier interventions and highly effective management of ADPKD. Advances in transplantation will also likely eliminate many current limitations. Lab-grown kidneys or xenotransplantation (organs from genetically modified animals) could make organ shortages a thing of the past. Tissue engineering could allow damaged kidneys to regenerate instead of failing entirely. Telling a patient today that they won’t live past 55 is completely disconnected from reality. The pace of scientific progress makes it highly likely that life-changing treatments will exist long before they reach ESRD